Transcripta Bio raised $24 million since its Series A to advance IND-enabling studies across its neuro pipeline, targeting autism spectrum disorder (ASD) and facioscapulohumeral muscular dystrophy. The company said the funding supports clinical preparation, while it also continues development in myotonic dystrophy and Huntington’s disease. The raise underscores a continued emphasis on translating RNA-centric biology into clinical programs, with near-term milestones focused on regulatory submission readiness rather than late-stage execution. For investors, it adds clarity on how smaller platforms are funding preclinical-to-clinic bridging work in neurodegenerative and neurodevelopmental indications.